Rabbit antithymocyte globulin as first-line therapy for severe aplastic anemia

Low response rate to ATG‐based immunosuppressive therapy in very severe aplastic anaemia — A Swedish nationwide cohort study

“…Indeed, in a logistic regression prediction model, patients with the combined low ARC at diagnosis and pretreatment VSAA had only a 19% probability of response. In previous studies, the response rates among VSAA patients have been reported to vary between 29.7% and 81% . Most of the VSAA patients in the present study received rATG (84.4%).…”

“…The response rates to hATG have been reported to be 50%-80% in VSAA patients 21,26 ; with rATG, the response rates are 29.7%-57%. 24,28,29 Thus, our data probably need to be interpreted with some caution. However, the majority of the above studies were singlecentre and registry reports with a low median age.…”

“…[5][6][7]11,12,[33][34][35][36][37] Thus far, only one prospective randomised study has compared first-line rATG and hATG treatment; it found a significantly better response rate (68% vs 37%) and 3-year survival (96% vs 76%) in the hATG group. 5 24 In a recent study from the MD Anderson Cancer Center, patients with a partial response had a shorter relapse-free survival than complete responders (P = .03); however, the authors found no difference in overall survival. 9 In our cohort, of the 12 relapsing patients, eight were in partial and four in complete response.…”

“…In previous studies, the response rates among VSAA patients have been reported to vary between 29.7% and 81%. [21][22][23][24][25][26][27][28] Most of the VSAA patients in the present study received rATG (84.4%). The response rates to hATG have been reported to be 50%-80% in VSAA patients 21,26 ; with rATG, the response rates are 29.7%-57%.…”

Efficiency of Modern Methods of Therapy of Acquired Aplastic Anemia in Children

“…Поскольку в Китае кроличий глобулин является единственным доступным препаратом для лечения апластической анемии и одобрен Государственной лекарственной Администрацией Китая как препарат первой линии при лечении тяжелой и сверхтяжелой форм АА. Ранняя смерть выявлена у 5,5% пациентов, а общий процент ответов составил 49% через 3 месяца, 60,3% -через 6 месяцев, 65,8% -через 9 месяцев и 68, 5% -через 12 месяцев [19].…”